Testing a GD2 CAR T cell therapy in children and young adults with diffuse midline glioma
Official title: CAR T Cells to Target GD2 for DMG
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing a CAR T cell therapy aimed at GD2 in young people with a brain tumor called diffuse midline glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary.
Read our full plain-language summary
What the trial team says
The CARMIGO Trial is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and young adults aged 2-16 years with Diffuse Midline Glioma (DMG). The study will evaluate the feasibility of generating the ATIMP, the safety and tolerability of the GD2CAR T-cell therapy and how effectively GD2CAR T-cells engraft, expand and persist following administration in patients with DMG.
Key facts
- Registry number
- NCT05544526
- Stage of testing
- Phase 1
- Conditions studied
- Diffuse Midline Glioma, H3 K27M-Mutant
Where it is running
This trial lists 1 site.
-
United Kingdom
- Great Ormond Street Hospital (London)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.